Mirtazapin Orion (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Orion, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and may be considered when other antidepressants are insufficient.

GNH USA supplies Mirtazapin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Mirtazapine belongs to the NaSSA class and is indicated for depressive disorders. It modulates neurotransmitter activity to improve mood and related symptoms.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Anxiety associated with depression: reduces anxiety features when used as adjunct therapy. - Sleep disturbances in depression: enhances sleep quality and reduces insomnia.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Serotonin syndrome, especially with other serotonergic agents - Suicidal thoughts or behavior, particularly early in treatment - Severe allergic reactions (e.g., rash, angioedema) - Hepatic dysfunction or jaundice

Before initiating therapy, clinicians should consider several safety aspects.

- Assess hepatic function: evaluate liver enzymes prior to treatment. - Monitor weight: be aware of potential weight gain during therapy. - Screen for suicidal ideation: especially during the first weeks of use. - Avoid abrupt discontinuation: taper the dose under medical supervision. - Use caution in elderly: increased risk of sedation and falls. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Other serotonergic agents (e.g., tramadol, triptans): increase the chance of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines): additive sedation. - Anticholinergic drugs: may exacerbate dry mouth. - Lithium: monitor for heightened side‑effect profile.